Home › Companies › Lumens Bios

Lumens Bios

루멘스바이오스 · 038060 · KOSDAQ
Filings, last 12 months
66
Supply contracts
0
Insider reports
3
Share & bond issues
3

At a glance

Lumens Bios filed 66 disclosures in the last 12 months, including 6 5% holder, 3 insider and 3 issuance. The most recent key filing was on Oct 21: Conversion price ₩1,142; if all converted, equal to 37.9% of shares outstanding.

Revenue for 2025 was ₩176B, up 0.8% on 2024. It made an operating loss of ₩5B. Debt was 47% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩72.9B and operating loss of ₩886.6M.

The 2025 annual report lists 92 employees with an average tenure of 8.4 years and average pay of ₩65.3M, #887 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩47M each on average. It paid no cash dividend for 2025. (주)디티씨 and related parties held 22.30% at year end.

Of 5 recent 5%+ holder reports, 2 raised and 1 cut a stake; the largest stake reported was 27.36% on Sep 22.

From the 2025 annual report

Employees
92
Average pay
₩65.3M
Average tenure
8.4 yrs
Avg. director pay
₩47M

Staff: 92 (74 men, 18 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩6B. Directors and auditors: 5, paid ₩235M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)디티씨 holds 21.97%; with 1 related party the group holds 22.30% of common shares at year end (from 3.08% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

2023
Revenue ₩171B
Op. profit ₩2.7B
Debt/equity 50%
2024
Revenue ₩174B
Op. profit -₩1.6B
Debt/equity 51%
2025
Revenue ₩176B
Op. profit -₩5B
Debt/equity 47%
2026 H1
Revenue ₩72.9B
Op. profit -₩886.6M
Debt/equity 41%
RevenueOperating profitOperating lossConsolidated where available · from periodic reports

5%+ holder reports

9/22Stake 27.36%+5.39pp
9/2Stake 21.97%0.00pp
9/2Stake 0.00%-21.97pp
8/13Stake 21.97%0.00pp
8/12Stake 21.97%+21.97pp

Key filings

10/12ExchangeTrading halt
9/21IssuanceAmendedCapital reductionCapital reduction of 80%.80%
9/17IssuanceAmendedCapital reduction
9/17IssuanceAmendedRights offering
9/14IssuanceAmendedCapital reduction
9/14IssuanceAmendedRights offering
9/11ExchangeTrading halt
9/11IssuanceCapital reduction
9/11IssuanceRights offering
9/10ExchangeSpin-off / split
4/16ExchangeExchange inquiry
4/15ExchangeExchange inquiry

Other filings

Links open the original filing on DART, in Korean.